Enzon begins PEG-hemoglobin multi-dose, multi-center trial in cancer patients.PISCATAWAY, N.J.--(BUSINESS WIRE)--June 24, 1996--Enzon, Inc. (NASDAQ NASDAQ in full National Association of Securities Dealers Automated Quotations U.S. market for over-the-counter securities. Established in 1971 by the National Association of Securities Dealers (NASD), NASDAQ is an automated quotation system that reports on \NMS See NetWare Management System. :ENZN) announced today that a multi-dose, multi-center clinical trial of its hemoglobin-based oxygen carrier, PEG-hemoglobin, has begun in cancer patients receiving radiation therapy. Patients entering this new trial will receive once-a-week infusions of PEG-hemoglobin followed by five days of radiation treatment. This will be repeated weekly for three weeks. The primary purpose of this trial is to evaluate safety related to multiple doses of PEG-hemoglobin in patients. It also offers an opportunity to observe tumor responses in patients receiving the combination of PEG-hemoglobin and radiation therapy. To date, as many as three injections of PEG-hemoglobin have been administered to patients participating in this clinical trial. In a previous Phase I safety trial, completed at the end of 1995, 34 normal volunteers received a single dose of PEG-hemoglobin in amounts up to the equivalent of 1.5 units of whole blood. The dose levels in the new trial will be approximately one-half to two- thirds of the highest dose used in the previous Phase I safety trial. The Company believes that, at this dose level, a sufficient amount of PEG-hemoglobin will remain in the blood stream to increase tumor oxygenation oxygenation /ox·y·gen·a·tion/ (ok?si-je-na´shun) 1. the act or process of adding oxygen. 2. the result of having oxygen added. during most of each five-day treatment cycle. "The Company is extremely excited that this clinical trial of PEG-hemoglobin in cancer patients is progressing" stated Peter G. Tombros, Enzon's president and chief executive officer. "It is our hope that it will be completed by the end of 1996." Enzon continues to dedicate its pilot manufacturing capability exclusively to the production of PEG-hemoglobin for additional clinical materials and commercial process development. The existing facility at the present scale is adequate to supply all PEG-hemoglobin needed for clinical trials. Enzon, Inc., is a biopharmaceutical company that develops, manufactures and markets enhanced therapeutics for life-threatening diseases, primarily in the areas of oncology, genetic diseases and blood substitutes. Enzon has two FDA FDA abbr. Food and Drug Administration FDA, n.pr See Food and Drug Administration. FDA, n.pr the abbreviation for the Food and Drug Administration. approved drugs -- ADAGEN , a treatment for Severe Combined Immunodeficiency Disease Noun 1. severe combined immunodeficiency disease - a congenital disease affecting T cells that can result from a mutation in any one of several different genes; children with it are susceptible to infectious disease; if untreated it is lethal within the first year or and ONCASPAR , for the treatment of Acute Lymphoblastic Leukemia acute lymphoblastic leukemia n. Abbr. ALL Lymphoblastic leukemia occurring mainly in older adults, characterized by rapid onset and progression of symptoms. Also called acute lymphocytic leukemia. , which is being marketed by Rhone-Poulenc Rorer Pharmaceuticals, Inc. The Company also pursues commercialization of its proprietary technologies through strategic partnering, including arrangements with Rhone-Poulenc Rorer Pharmaceuticals Inc., Schering Corporation, Eli Lilly Eli Lilly can refer to:
20 Kingsbridge Road, Piscataway, NJ 08854 Phone: (908) 980-4500 Fax:(908) 980-5911 http://www.enzon.com CONTACT: Kimberly Cooper Communications Specialist (908) 980-4577 |
|
||||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion